Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MIRM 
Mirum Pharmaceuticals Inc (MIRM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: MIRM (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $68.6
1 Year Target Price $68.6
| 6 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 12.47% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.49B USD | Price to earnings Ratio - | 1Y Target Price 68.6 |
Price to earnings Ratio - | 1Y Target Price 68.6 | ||
Volume (30-day avg) 10 | Beta 0.95 | 52 Weeks Range 34.47 - 54.23 | Updated Date 07/4/2025 |
52 Weeks Range 34.47 - 54.23 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -20.39% | Operating Margin (TTM) -13.61% |
Management Effectiveness
Return on Assets (TTM) -7.11% | Return on Equity (TTM) -33.06% |
Valuation
Trailing PE - | Forward PE 39.68 | Enterprise Value 2471140864 | Price to Sales(TTM) 6.57 |
Enterprise Value 2471140864 | Price to Sales(TTM) 6.57 | ||
Enterprise Value to Revenue 6.52 | Enterprise Value to EBITDA -8.85 | Shares Outstanding 49534700 | Shares Floating 39545044 |
Shares Outstanding 49534700 | Shares Floating 39545044 | ||
Percent Insiders 1.91 | Percent Institutions 114.12 |
Upturn AI SWOT
Mirum Pharmaceuticals Inc
Company Overview
History and Background
Mirum Pharmaceuticals Inc. was founded in 2011. It focuses on developing and commercializing therapies for rare liver diseases. Significant milestones include the approval of LIVMARLI (maralixibat) and the acquisition of other assets to expand its pipeline.
Core Business Areas
- Rare Liver Disease Therapies: Mirum develops and commercializes therapies for rare liver diseases, including cholestatic liver diseases in children and adults. Their primary focus is on treating Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), and biliary atresia.
Leadership and Structure
The leadership team includes Chris Peetz (President and CEO), Peter Daniels (Chief Medical Officer), and Ian Clements (Chief Financial Officer). The company operates with a functional organizational structure aligned to support drug development, commercialization, and corporate operations.
Top Products and Market Share
Key Offerings
- LIVMARLI (maralixibat): LIVMARLI is an ileal bile acid transporter (IBAT) inhibitor approved for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older and for PFIC type 2. Its major competitors include other therapies managing the symptoms of these rare diseases, and ultimately, potential gene therapies.
- LIVMARLI (maralixibat): LIVMARLI is indicated for biliary atresia. The competitors include Kasai procedure which is a surgical procedure and potential transplant.
Market Dynamics
Industry Overview
The industry focuses on rare diseases, which often have unmet medical needs and orphan drug designation benefits. It involves high development costs and regulatory hurdles, but successful products can command premium pricing.
Positioning
Mirum is positioned as a leader in developing and commercializing therapies for rare liver diseases, particularly cholestatic conditions. Their competitive advantage lies in their focus on specific rare diseases and their established clinical data and regulatory approvals.
Total Addressable Market (TAM)
The TAM for rare liver diseases is substantial and growing, driven by increasing awareness and improved diagnostic capabilities. Mirum's market position targets the cholestatic liver disease segment, with potential expansion into related conditions.
Upturn SWOT Analysis
Strengths
- Approved product (LIVMARLI)
- Focus on rare diseases with unmet needs
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on a limited number of products
- High dependence on regulatory approvals
- Limited commercial infrastructure relative to larger pharmaceutical companies
- High R&D expenses
Opportunities
- Expansion into new rare liver diseases
- Development of new formulations or indications for existing products
- Strategic partnerships and collaborations
- Geographic expansion
Threats
- Competition from other pharmaceutical companies developing therapies for rare liver diseases
- Regulatory challenges and delays
- Pricing and reimbursement pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- ALNY
- ICPT
- GILD
Competitive Landscape
Mirum competes with companies developing therapies for rare liver diseases. Their advantage is LIVMARLI, but competitors are also developing therapies for similar indications. Competition is based on efficacy, safety, and market access.
Major Acquisitions
ALEX Therapeutics
- Year: 2024
- Acquisition Price (USD millions): 97.5
- Strategic Rationale: This acquisition aimed to enhance Mirum's digital therapeutic capabilities and expand its product pipeline into patient support tools.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is driven by the successful launch and market penetration of LIVMARLI. Future growth depends on continued market adoption, expansion into new indications, and the development of new products.
Future Projections: Analyst estimates project continued revenue growth based on increasing market share and potential new product launches. This relies on positive clinical data and regulatory outcomes.
Recent Initiatives: Recent initiatives include expanding the label for LIVMARLI, advancing clinical trials for other liver diseases, and exploring strategic partnerships.
Summary
Mirum is a biopharmaceutical company specializing in rare liver diseases, and while they have promising products like LIVMARLI, their reliance on a limited number of products and ongoing losses present challenges. Strong IP and focus are strengths, but competitive pressure and regulatory hurdles need to be navigated. Growth will be driven by expanding indications, new product launches, and strategic initiatives. The recent acquisition of ALEX Therapeutics seems to be a step in the right direction to diversify its revenue.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mirum Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 2019-07-18 | CEO & Director Mr. Christopher Peetz | ||
Sector Healthcare | Industry Biotechnology | Full time employees 334 | Website https://www.mirumpharma.com |
Full time employees 334 | Website https://www.mirumpharma.com | ||
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.